Disclosures for "Regional Brain 3R/4R RT-QuIC Seeding Reflects Patterns of AD Pathology and Correlates with Histopathological Burden of Disease"
-
The institution of Dr. Coughlin has received research support from American Academy of Neurology. The institution of Dr. Coughlin has received research support from NIA. The institution of Dr. Coughlin has received research support from NINDS.
-
Ms. Standke has nothing to disclose.
-
Mr. Rachakonda has nothing to disclose.
-
Ms. Huntley has nothing to disclose.
-
Mr. Kim has nothing to disclose.
-
Miss Swanberg has nothing to disclose.
-
Ms. Andreasson has nothing to disclose.
-
Dr. Manca has nothing to disclose.
-
Miss Thomas has nothing to disclose.
-
Dr. Galasko has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Galasko has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for vTv Therapeutics. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fujirebio. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Esai. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BioMed Central.
-
Prof. Kraus has nothing to disclose.
-